Protagenic Therapeutics, Inc. PTIX
0.51 USD 0.00 (+0.00%)
Nov 11, 2026, 11:02 AM EST
0.51 Day range 0.51
0.128 52-week range 2.38
- YTD
- -60.77%
- 1 year
- -73.02%
News
accessnewswire.com Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder FDA raises no objection to the Company's planned Phase 1 program design, dose-escalation approach, or CMC and nonclinical packages; IND submission remains on track for the fourth quarter of 2026 NEW…
accessnewswire.com Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model As published in Behavioural Pharmacology, two days of PT00114 treatment reduced corticosterone levels and attenuated anxiety-like behavior in chronically stressed rats; a known CRF₁ receptor…
accessnewswire.com Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based therapies for stress-related…
accessnewswire.com Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114 NEW YORK, NY / ACCESS Newswire / April 23, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company pioneering first-in-class neuropeptide therapies for…
defenseworld.net Contrasting Vanda Pharmaceuticals (NASDAQ:VNDA) and Atrinsic (NASDAQ:PTIX) Vanda Pharmaceuticals (NASDAQ: VNDA - Get Free Report) and Atrinsic (NASDAQ: PTIX - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two…
accessnewswire.com Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114 NEW…
accessnewswire.com Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market Move strengthens market visibility, supports liquidity and real-time quote access as PT00114 advances toward Phase 2 in 2026 NEW YORK CITY, NY / ACCESS Newswire / March 10, 2026 / Protagenic…
defenseworld.net Atrinsic (NASDAQ:PTIX) Shares Up 10.9% – Should You Buy? Atrinsic Inc. (NASDAQ: PTIX - Get Free Report)'s stock price was up 10.9% during trading on Tuesday. The company traded as high as $0.50 and last traded at $0.50. Approximately 2,974 shares traded…
defenseworld.net Head-To-Head Contrast: Praxis Precision Medicines (NASDAQ:PRAX) versus Atrinsic (NASDAQ:PTIX) Atrinsic (NASDAQ: PTIX - Get Free Report) and Praxis Precision Medicines (NASDAQ: PRAX - Get Free Report) are both medical companies, but which is the better business? We will contrast the two…
benzinga.com Protagenic Therapeutics Reports Topline Phase 1 Safety Data For PT00114, Was Well Tolerated Across All Dose Ranges Studied; Paves Way For Phase 2 In Stress-Related Neuropsychiatric Conditions Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditionsNEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 /…
accessnewswire.com Results from Phase 1 Multiple-Dose Study of PT00114 Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 /…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
accessnewswire.com Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing…
defenseworld.net Atrinsic (NASDAQ:PTIX) Trading Up 2.5% – Time to Buy? Atrinsic Inc. (NASDAQ: PTIX - Get Free Report) shares were up 2.5% on Friday. The stock traded as high as $2.15 and last traded at $2.07. Approximately 56,058 shares were traded during trading, a…
benzinga.com Protagenic Therapeutics Completes Enrollment, Dosing In Its Multiple Ascending Dose Phase 1 Trial Evaluating PT00114 Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and neurodegenerative disorders, today announced the…
accessnewswire.com Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study NEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Protagenic Therapeutics Expects To File Its Quarterly Report On Form 10-Q For The Period Ended June 30, 2025 In The Near Future, Following A Delay Attributable To The Completion Of Merger-Related Consolidation Of Financial Statements, Including Purchase Accounting Adjustments, Pro Forma Financial Information, And Related Disclosures NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel neuro-active peptide therapies, today announced that it…
accessnewswire.com Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance Delay Attributable to Merger-Related Financial Consolidation NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX), a biopharmaceutical company developing…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Protagenic Therapeutics (PTIX) Shares Surge On Clinical Trial Progress Shares of Protagenic Therapeutics are trading sharply higher Thursday afternoon. The stock soared over 100% midday after the company announced a key clinical milestone.
benzinga.com S&P 500 Moves Lower; Walmart Shares Fall After Q2 Results - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Dow Dips Over 100 Points; US Initial Jobless Claims Increase 
benzinga.com Protagenic Completes First Dose Injections In Phase I Multiple-Dose Study Of PT00114; Topline Safety Data Expected By September; Phase 2 Launch Targeted For Q1 2026 Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a…
accessnewswire.com Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026 NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a…
benzinga.com Protagenic Therapeutics Announces Major Restructuring: Transitions To Virtual Operating Model, Cuts $8M In Annual Costs, Halts Preclinical Programs, Terminates CEO And COO, Changes Fiscal Year-End, And Refocuses On Lead Clinical Trial For PT00114 Item 2.05 Costs Associated with Exit or Disposal Activities. On August 8, 2025, the Board of Directors (the "Board") of Protagenic Therapeutics, Inc. (the "Company" or "Protagenic") approved a…
prismmediawire.com Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates NEW YORK, NY and SANTA BARBARA, CA, July 30, 2025 – PRISM MediaWire – Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office…
globenewswire.com Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates NEW YORK and SANTA BARBARA, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
accessnewswire.com Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Nasdaq Falls 100 Points; Home Depot Sales Top Views 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket 
benzinga.com Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday.
benzinga.com Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Protagenic Therapeutics (PTIX) Stock Soars 240% On Phytanix Merger Protagenic Therapeutics shares soared 240% Monday on its all-stock merger with Phytanix Bio. New Phytanix targets CNS disorders with an expanded diverse pipeline and experienced team.
businesswire.com PTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Protagenic Therapeutics, Inc. (NASDAQ: PTIX) and Phytanix Bio Inc. is fair to…
benzinga.com Dow Tumbles 200 Points; ZIM Integrated Shipping Services Posts Upbeat Earnings 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com As Calculated On A Fully Diluted Basis, Post-Combination Pre-Financing Ownership Will Be Approximately 35% For The Pre-Combination Stockholders Of The Company And Approximately 65% For Phytanix Bio Stockholders. Structure of CombinationUnder the terms of the Exchange Agreement, the Company, in exchange for all of the outstanding shares of Phytanix Bio, issued on a pro rata basis to each of the common…
benzinga.com Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - benzinga.com Protagenic Therapeutics Q1 EPS $(2.75) Up From $(5.44) YoY Protagenic Therapeutics (NASDAQ:PTIX) reported quarterly losses of $(2.75) per share. This is a 49.45 percent increase over losses of $(5.44) per share from the same period last year.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session